Cargando…

Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study

BACKGROUND: Myelodysplastic syndromes (MDS) are characterized by ineffective erythropoiesis with dysplastic bone marrow leading to peripheral cytopenia, risk of infection, and progression to acute myelogenous leukemia. Maitake mushroom beta-glucan, a dietary supplement, stimulates hematopoietic prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wesa, Kathleen M., Cunningham-Rundles, Susanna, Klimek, Virginia M., Vertosick, Emily, Coleton, Marci I., Yeung, K. Simon, Lin, Hong, Nimer, Stephen, Cassileth, Barrie R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317517/ https://www.ncbi.nlm.nih.gov/pubmed/25351719 http://dx.doi.org/10.1007/s00262-014-1628-6

Ejemplares similares

Maitake Mushroom Extracts Ameliorate Progressive Hypertension and Other Chronic Metabolic Perturbations in Aging Female Rats
por: Preuss, Harry G., et al.
Publicado: (2010)

A safety and efficacy pilot study of acupuncture for the treatment of chronic lymphoedema
por: Cassileth, Barrie R, et al.
Publicado: (2011)

Acupuncture in the Treatment of Upper-Limb Lymphedema: Results of a Pilot Study
por: Cassileth, Barrie R, et al.
Publicado: (2013)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

A polysaccharide-peptide with mercury clearance activity from dried fruiting bodies of maitake mushroom Grifola frondosa
por: Zhang, Weiwei, et al.
Publicado: (2018)

Synergistic immuno-modulatory activity in human macrophages of a medicinal mushroom formulation consisting of Reishi, Shiitake and Maitake
por: Mallard, Brody, et al.
Publicado: (2019)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
por: Xie, Xiaoqing, et al.
Publicado: (2021)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
por: Lucero, Josephine, et al.
Publicado: (2023)

Bioactive Ingredients and Medicinal Values of Grifola frondosa (Maitake)
por: Wu, Jian-Yong, et al.
Publicado: (2021)

Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform
por: Valent, P, et al.
Publicado: (2008)

Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning
por: Sallman, David A., et al.
Publicado: (2022)

Risk of Disease Progression in Low-Risk MDS is Linked to Distinct Epigenetic Subtypes
por: Qin, Tingting, et al.
Publicado: (2019)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
por: Blum, Sabine, et al.
Publicado: (2021)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
por: Hoff, Fieke W., et al.
Publicado: (2023)

Metabolomics Profiling of White Button, Crimini, Portabella, Lion’s Mane, Maitake, Oyster, and Shiitake Mushrooms Using Untargeted Metabolomics and Targeted Amino Acid Analysis
por: Uffelman, Cassi N., et al.
Publicado: (2023)

Palliative care: Progress, needs, and challenges
por: Cassileth, Barrie R
Publicado: (2012)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020)

Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL).
por: Sozzi, G., et al.
Publicado: (1990)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS)
por: Yao, Chi-Yuan, et al.
Publicado: (2016)

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic
por: Feld, Jonathan, et al.
Publicado: (2020)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

Antitumoral and antimetastatic activity of Maitake D-Fraction in triple-negative breast cancer cells
por: Alonso, Eliana Noelia, et al.
Publicado: (2018)

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
por: Stahl, Maximilian, et al.
Publicado: (2023)

Evaluation of different scoring systems and gene mutations for the prognosis of myelodysplastic syndrome (MDS) in Chinese population
por: Du, Meng-yi, et al.
Publicado: (2020)

COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study
por: Padron, Eric, et al.
Publicado: (2021)

Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)
por: Ali, Abdullah Mahmood, et al.
Publicado: (2023)

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
por: Brunner, Andrew M., et al.
Publicado: (2022)

S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
por: Komrokji, Rami S., et al.
Publicado: (2023)

Maitake Pro4X has anti‐cancer activity and prevents oncogenesis in BALBc mice
por: Roldan‐Deamicis, Agustina, et al.
Publicado: (2016)

Antioxidant Properties and Antioxidant Compounds of Various Extracts from the Edible Basidiomycete Grifola Frondosa (Maitake)
por: Yeh, Jan-Ying, et al.
Publicado: (2011)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
por: Jensen, Oda, et al.
Publicado: (2022)

The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients
por: Stauder, Reinhard
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_onfjra3848348kur8hqtd3mico